Further research on this phenomenon revealed that in different mouse models of AD, for example, in APP/PS1 mice [244], Tg2576 mice [245], and PS19 mice, a model of tauopathy [246], antagonists of CRH receptor 1 (CRH-R1) improved memory deficits and decreased Aβ and Tau hyperphosphorylation. Here, MAPT is linked to Alzheimer disease.